These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28929869)

  • 61. An analysis of China's national essential medicines policy.
    Guan X; Liang H; Xue Y; Shi L
    J Public Health Policy; 2011 Aug; 32(3):305-19. PubMed ID: 21614030
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Non-Adherence to Prescribed Therapies: Pharmacare's Existential Challenge.
    Gogovor A; Nemis-White J; Torr E; MacPherson N; Martin L; Aylen J; Manness LJ; Montague T
    Healthc Q; 2019 Jul; 22(2):21-26. PubMed ID: 31556375
    [TBL] [Abstract][Full Text] [Related]  

  • 63. An industry in evolution.
    Blissenbach HF
    Med Interface; 1995 Oct; 8(10):80-1, 88. PubMed ID: 10152328
    [No Abstract]   [Full Text] [Related]  

  • 64. The redistributive effect of the move from age-based to income-based prescription drug coverage in British Columbia, Canada.
    Hanley GE; Morgan S; Barer M; Reid RJ
    Health Policy; 2011 Jul; 101(2):185-94. PubMed ID: 21255859
    [TBL] [Abstract][Full Text] [Related]  

  • 65. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
    Gleeson D; Lopert R; Reid P
    Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Distributional consequences of the transition from age-based to income-based prescription drug coverage in British Columbia, Canada.
    Hanley GE; Morgan S; Hurley J; van Doorslaer E
    Health Econ; 2008 Dec; 17(12):1379-92. PubMed ID: 18189226
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Association of increased emergency rooms costs for patients without access to necessary medications.
    Watanabe JH; Ney JP
    Res Social Adm Pharm; 2015; 11(4):499-506. PubMed ID: 25487421
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Contrasting Canada and the United States: what did they get right and wrong about healthcare?
    Murray J
    Medscape J Med; 2008; 10(11):256. PubMed ID: 19099006
    [No Abstract]   [Full Text] [Related]  

  • 69. Drug coverage insurance as a novel element of private health insurance in Poland.
    Czerw A; Religioni U
    Acta Pol Pharm; 2013; 70(4):763-7. PubMed ID: 23923401
    [TBL] [Abstract][Full Text] [Related]  

  • 70. How to pay for national pharmacare.
    Wolfson MC; Morgan SG
    CMAJ; 2018 Nov; 190(47):E1384-E1388. PubMed ID: 30478216
    [No Abstract]   [Full Text] [Related]  

  • 71. Understanding the effects of Medicare Part D from key stakeholders' perspectives: Important progress, but abundant research opportunities remain.
    Urmie JM; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):85-9. PubMed ID: 20511107
    [No Abstract]   [Full Text] [Related]  

  • 72. [Co-payment and the hospital pharmacy].
    Lamas Díaz MJ; Delgado Sánchez O; Poveda Andrés JL
    Farm Hosp; 2013; 37(5):345-7. PubMed ID: 24128094
    [No Abstract]   [Full Text] [Related]  

  • 73. A national drug agency.
    West R; Borden EK; Collet JP; Rawson NS; Tonks RS
    CMAJ; 2003 Apr; 168(8):962-3. PubMed ID: 12695372
    [No Abstract]   [Full Text] [Related]  

  • 74. Drug coverage in Canada: gaps and opportunities.
    Clement F; Memedovich KA
    J Psychiatry Neurosci; 2018 May; 43(3):148-150. PubMed ID: 29688870
    [No Abstract]   [Full Text] [Related]  

  • 75. Do provincial drug benefit initiatives create an effective policy lab? The evidence from Canada.
    Pomey MP; Morgan S; Church J; Forest PG; Lavis JN; McIntosh T; Smith N; Petrela J; Martin E; Dobson S
    J Health Polit Policy Law; 2010 Oct; 35(5):705-42. PubMed ID: 21123668
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Experience with providing drugs for seniors in Canada.
    Gray J
    Am J Geriatr Cardiol; 2005; 14(6):313-6. PubMed ID: 16276129
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prescription drug benefits and Canada's uninsured.
    Dewa CS; Hoch JS; Steele L
    Int J Law Psychiatry; 2005; 28(5):496-513. PubMed ID: 16125777
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries.
    Kennedy J; Morgan S
    Clin Ther; 2009 Jan; 31(1):213-9. PubMed ID: 19243719
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Gap in drug coverage often causes lapses in adherence to drug regimen, study shows.
    Levenson D
    Rep Med Guidel Outcomes Res; 2004 Sep; 15(18):9-10, 12. PubMed ID: 15452947
    [No Abstract]   [Full Text] [Related]  

  • 80. Impact of drug plans on adherence to and the cost of antihypertensive medications among patients covered by a universal drug insurance program.
    Després F; Perreault S; Lalonde L; Forget A; Kettani FZ; Blais L
    Can J Cardiol; 2014 May; 30(5):560-7. PubMed ID: 24613090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.